Maja Kuharic

Dr. Maja Kuharic

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2024 in Value in Health
Verified
Journal Article
Open access
MKMaja Kuharic
Maja Kuharic
BMBrendan Mulhern
Brendan Mulhern
LSLisa K. Sharp
Lisa K. Sharp
RTRobin S. Turpin
Robin S. Turpin
APA. Simon Pickard
A. Simon Pickard
Several measures have been used or developed to capture the health and well-being of caregivers, including the EQ Health and Well-being (EQ-HWB) and its short form, EQ-HWB-S. This study aimed to evaluate the psychometric properties and construct validity of the EQ-HWB/EQ-HWB-S in a US caregiver population. A cross-sectional survey was conducted involving 504 caregivers. Eligible participants were 18+ years old, provided unpaid care to a relative/friend aged 18+ in the past six months, and spent on average of at least one hour per week caregiving. Survey included the following measures: EQ-HWB, ASCOT-Carer, CarerQol and EQ-5D-5L. Psychometric properties were assessed using response distributions, floor/ceiling effects, Spearman's correlation for convergent validity, and effect sizes (ES) for known group validity (KGV) based on caregiving situations and intensity. The average age of caregivers was 49.2 (SD=15.4), with 57.5% being female. More than half (54.4%) reported high caregiving intensity, and 68.3% lived with the care recipient. The EQ-HWB-S index showed a strong positive correlation with the EQ-5D-5L (rs=0.72), ASCOT (rs=0.54), and CarerQol (rs=0.54) indices. Notably, the EQ-HWB-S index showed the largest ES among measures in differentiating caregiving scenarios with a large ES for caregiver's general health (d=1.00) and small ES for caregiving intensity (d=0.39). Results support construct validity of EQ-HWB and EQ-HWB-S as measures for assessing health and well-being of adult informal caregivers in comparison with other validated instruments. Differing levels of KGV across anchors emphasize the importance of selecting appropriate measures for caregivers, depending on research question and/or intervention aims.

14 March 2024 in Value in Health
Verified
Journal Article
Open access
MKMaja Kuharic
Maja Kuharic
APA. Simon Pickard
A. Simon Pickard
CMClara Mukuria
Clara Mukuria
AFAureliano Paolo Finch
Aureliano Paolo Finch
The EQ Health and Well-being, EQ-HWB (25-item) and the EQ-HWB-S (9-item), are new generic measures of health and well-being. The purpose of this study was to examine the measurement properties of the EQ-HWB and EQ-HWB-S measures in relation to the EQ-5D-5L among the Italian general population. A cross-sectional survey was conducted from October 2020 to February 2021, followed by secondary analysis of collected data from Italian adults. This analysis included response pattern distributions, correlation strength, and known-group comparison. Known-group comparison was assessed using effect sizes (ES) across health conditions, caregiver status, and social care usage. The EQ-HWB-S index-based score was based on the UK pilot value set, whereas the Italian value set was used for scoring the EQ-5D-5L index. Out of the 1182 participants, 461 reported having a chronic condition, 185 identified as caregivers, and 42 were social care users. EQ-HWB items (7.5%) showed fewer ceiling effects than EQ-5D-5L items (34.7%). Strong correlations (rs > 0.5) were found between overlapping EQ-HWB and EQ-5D-5L items. EQ-HWB-S and EQ-5D-5L index scores demonstrated similar discrimination based on symptomatic chronic conditions (ES d = 0.68 vs d = 0.71), but EQ-HWB-S had slightly higher ES for social care users (ES d = 0.84 vs d = 0.74). Initial evidence supports the validity of EQ-HWB/EQ-HWB-S because outcome measures in the Italian population. EQ-HWB-S performed comparably to EQ-5D-5L among patients and was better in differentiating social care users. A slight decrease in discriminative properties for caregivers was observed when transitioning from EQ-HWB to EQ-HWB-S.

17 April 2024 in Quality of Life Research
Verified
Journal Article
Closed access
PDF file
MKMaja Kuharic
Maja Kuharic
BMBrendan Mulhern
Brendan Mulhern
LSLisa K. Sharp
Lisa K. Sharp
RTRobin S. Turpin
Robin S. Turpin
APA. Simon Pickard
A. Simon Pickard

1 December 2024 in JCO Oncology Practice
Verified
Journal Article
Open access
BYBetina Yanez
Betina Yanez
LPLaura M. Perry
Laura M. Perry
JPJohn Devin Peipert
John Devin Peipert
MKMaja Kuharic
Maja Kuharic
CTChloe Taub
Chloe Taub
SKSheetal M. Kircher
Sheetal M. Kircher
PURPOSE: Financial hardship (FH) is a complex issue in cancer care, affecting material conditions, well-being, and coping behaviors. This study aimed to longitudinally examine FH, anxiety, depressive symptoms, and their associations while incorporating social determinants of health and health care cost covariates in a sample of patients diagnosed with cancer. METHODS: This prospective, longitudinal cohort study analyzed data from 2,305 participants from the Northwestern University Improving the Management of Symptoms during and following Cancer Treatment trial. Outcomes assessed at baseline and at 3, 6, 9, and 12 months postbaseline included depressive symptoms, anxiety, and FH. Analysis involved random intercept cross-lagged panel models to explore between- and within-person effects, incorporating factors such as age, sex, insurance status, neighborhood area deprivation, health care charges, out-of-pocket costs, and health literacy. RESULTS: The cohort had a mean age of 60.7 (standard deviation [SD] = 12.7) years and was mostly female (64.9%) and White (86.2%). Correlations were found between FH and depressive symptoms ( r = 0.310) and anxiety ( r = 0.289). A predictive relationship was observed between FH and depressive symptoms, with baseline and 6-month depressive symptom levels predicting later FH (baseline β = .079, P = .070; 6-month β = .072, P = .081) and 9-month FH significantly predicting 12-month depressive symptoms (β = .083, P = .025), even after accounting for health care charges and out-of-pocket costs. Baseline and 9-month anxiety showed a predictive relationship with subsequent FH (baseline β = .097, P = .023; 9-month β = .071, P = .068). CONCLUSION: FH emerged as a prominent issue, with nearly half of participants experiencing some level of FH. Depressive symptoms and anxiety were related to FH. These findings underscore the need for a comprehensive approach in cancer care that concurrently addresses anxiety, depressive symptoms, and FH, recognizing their interconnected impact.

5 February 2024 in SSM - Qualitative Research in Health
Verified
Journal Article
Open access
MKMaja Kuharic
Maja Kuharic
LSLisa K. Sharp
Lisa K. Sharp
RTRobin S. Turpin
Robin S. Turpin
BMBrendan Mulhern
Brendan Mulhern
TLTodd A. Lee
Todd A. Lee
APA. Simon Pickard
A. Simon Pickard

2 August 2024 in Journal of the American Medical Informatics Association
Verified
Journal Article
Open access
PDF file
DCDavid Cella
David Cella
MKMaja Kuharic
Maja Kuharic
JPJohn Devin Peipert
John Devin Peipert
KBKaty Bedjeti
Katy Bedjeti
SGSofia F Garcia
Sofia F Garcia
CBCynthia Barnard
Cynthia Barnard
To assess the use of a co-designed patient-reported outcome (PRO) clinical dashboard and estimate its impact on shared decision-making (SDM) and symptomatology in adults with advanced cancer or chronic kidney disease (CKD). We developed a clinical PRO dashboard within the Northwestern Medicine Patient-Reported Outcomes system, enhanced through co-design involving 20 diverse constituents. Using a single-group, pretest-posttest design, we evaluated the dashboard's use among patients with advanced cancer or CKD between June 2020 and January 2022. Eligible patients had a visit with a participating clinician, completed at least two dashboard-eligible visits, and consented to follow-up surveys. PROs were collected 72 h prior to visits, including measures for chronic condition management self-efficacy, health-related quality of life (PROMIS measures), and SDM (collaboRATE). Responses were integrated into the EHR dashboard and accessible to clinicians and patients. We recruited 157 participants: 66 with advanced cancer and 91 with CKD. There were significant improvements in SDM from baseline, as assessed by collaboRATE scores. The proportion of participants reporting the highest level of SDM on every collaboRATE item increased by 15 percentage points from baseline to 3 months, and 17 points between baseline and 6-month follow-up. Additionally, there was a clinically meaningful decrease in anxiety levels over study period (T-score baseline: 53; 3-month: 52; 6-month: 50; P < .001), with a standardized response mean (SRM) of −0.38 at 6 months. PRO clinical dashboards, developed and shared with patients, may enhance SDM and reduce anxiety among patients with advanced cancer and CKD.